Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
351 studies found for:    leukemia [CONDITION] AND child [AGE-GROUP] | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Vincristine in induction;   Drug: Daunorubicin in induction;   Drug: Prednisone in induction;   Drug: Metotrexato in induction;   Drug: Cytarabine in induction;   Drug: Hydrocortisone in induction;   Drug: Idarubicin in induction-2;   Drug: Fludarabine in induction-2;   Drug: Ara-C in induction-2;   Drug: G-CSF in induction-2;   Drug: Dexamethasone in consolidation-1;   Drug: Vincristrine in consolidation-1;   Drug: Metotrexato in consolidation-1;   Drug: PEG-ASP in consolidation-1;   Drug: Dexamethasone in consolidation-2;   Drug: ARA-C in consolidation-2;   Drug: PEG-ASP in consolidation-2;   Drug: Dexamethasone in consolidation-3;   Drug: Vincristine in consolidation-3;   Drug: Metotrexato in consolidation-3;   Drug: PEG-ASP in consolidation-3;   Procedure: allogeneic HSCT;   Procedure: Allo HSCT with reduced-intensity conditioning
22 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
23 Not yet recruiting Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Leukemia
Interventions: Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);   Drug: Cytarabine(Actavis Italy S.p.A);   Drug: Fludarabine (Bayer);   Drug: granulocyte colony-stimulating factor (KirinKunpeng);   Drug: rabbit ATG(Sanofi/Genzyme)
24 Available Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
25 Not yet recruiting Hematopoietic Stem Cell Microtransplantation for in AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic stem cell microtransplantation-long-term;   Procedure: hematopoietic stem cell microtransplantation-short-term;   Drug: Conditioning for CR group;   Drug: Conditioning for Non-CR group
26 Recruiting Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: SAHA;   Procedure: Stem Cell Infusion (SCT);   Drug: Thymoglobulin
27 Recruiting Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Condition: Leukemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Procedure: Alloreactive NK infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Tacrolimus;   Drug: Methotrexate
28 Recruiting The Oronasal Microbiota in Pediatric Oncology Patients
Conditions: Acute Myeloid Leukemia;   Hematologic Malignancy;   Bone Marrow Transplantation
29 Recruiting A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Allopurinol
30 Recruiting N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
Condition: Childhood Leukemia Survivors
31 Recruiting HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: idarubicin;   Biological: microtransplantation
32 Recruiting Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   Leukemia Relapse
Intervention: Biological: Collection of blood samples
33 Recruiting Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
Conditions: Refractory B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia
Intervention: Genetic: UCART19
34 Recruiting Allogeneic Stem Cell Transplantation for Children With CML
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Drug: ATG;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: bone marrow or peripheral blood stem cells
35 Recruiting Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia
Condition: Pediatric Acute Leukemia
Intervention: Other: blood draw
36 Recruiting Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Condition: Acute Lymphoblastic Leukaemia
Interventions: Drug: VP16;   Radiation: TBI;   Drug: Thiotepa;   Drug: Treosulfan;   Drug: Fludarabine;   Drug: Busulfan
37 Recruiting Matched Targeted Therapy For High-Risk Leukemias
Conditions: Recurrent, Refractory, or High Risk Leukemias;   Matched Targeted Therapy
Intervention: Genetic: Leukemia Profiling
38 Recruiting A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Condition: CD19+ Acute Leukemia
Intervention: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
39 Recruiting Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
40 Recruiting HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: IDA;   Radiation: TBI;   Drug: CTX;   Drug: VP-16

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.